Inspire Pharmaceuticals Announces Outcome Of FDA Meeting On Dry Eye Program; Additional Information To Be Provided To FDA As Next Step

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) met with the U.S. Food and Drug Administration (FDA) on March 22, 2006 regarding the approvable letter received from the FDA on December 1, 2005 for diquafosol tetrasodium ophthalmic solution. The meeting with the FDA involved a broad discussion of Inspire's dry eye clinical program for diquafosol.